Fresh Tracks Therapeutics (FRTX) AI Stock Analysis

• Market Cap: $5.59M
• Dividend Yield: N/A
• Average Volume (3M): 2.67K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.19
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 4
• Sector: Healthcare
• Sector Strength: 77
• Industry: Biotechnology
• EPS (TTM): -1.41
• Shares Outstanding: 7,811,000
• 10 Day Avg. Volume: 1,578
• 30 Day Avg. Volume: 2,667
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.70
• Price to Cash Flow (P/CF): -1.20
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Fresh Tracks Therapeutics faces significant financial performance challenges due to ongoing losses and negative cash flow, despite some revenue growth and a strong equity position. Technical indicators suggest the stock may be overbought, increasing the risk of a price pullback. The negative P/E ratio and lack of dividend yield further weigh on its valuation, leading to a generally unfavorable outlook.

Fresh Tracks Therapeutics Business Overview & Revenue Model

Company Description

Fresh Tracks Therapeutics (FRTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies targeting dermatological diseases and conditions. Operating within the biotechnology and healthcare sectors, FRTX is dedicated to addressing unmet medical needs through its diverse pipeline of therapeutic candidates, leveraging cutting-edge research and development to deliver effective solutions to patients.

How the Company Makes Money

Fresh Tracks Therapeutics generates revenue primarily through the development and commercialization of its proprietary dermatological therapies. The company seeks to monetize its therapeutic candidates through various channels, including direct sales of approved products, collaborative partnerships with larger pharmaceutical companies, and licensing agreements. These partnerships often involve milestone payments and royalties, providing a significant boost to the company's earnings. Additionally, FRTX may engage in research and development collaborations, receiving funding and support in exchange for sharing intellectual property or co-developing products. These revenue streams are pivotal in sustaining the company's operations and fueling further innovation in its pipeline.

Fresh Tracks Therapeutics Financial Statement Overview

Summary

Fresh Tracks Therapeutics shows some positive revenue growth and strong equity positioning, but persistent operational losses, negative margins, and cash flow challenges hinder financial stability. The company must focus on achieving profitability and improving cash flow sustainability to enhance its financial outlook.

Income Statement

The company has shown a positive revenue growth rate of 15.32% from 2022 to 2023, which is a positive trend. However, the net profit margin remains negative due to consistent net losses, and margins such as EBIT and EBITDA are also negative, indicating ongoing operational challenges. Profitability remains a significant concern despite revenue gains.

Balance Sheet

The balance sheet reflects a relatively strong equity position with zero total debt and a high equity ratio. However, the company has experienced decreasing total assets over the years, and while the debt-to-equity ratio is favorable, the company needs to maintain asset growth for improved financial health.

Cash Flow

The company's free cash flow has improved significantly, showing a positive growth rate, but it remains negative overall. The operating cash flow to net income ratio indicates stronger cash flow management compared to prior periods, yet continued negative cash flows highlight ongoing liquidity issues.

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
8.01M	6.94M	404.00K	1.82M	7.92M
	Gross Profit
8.01M	-7.10M	-27.83M	-9.39M	-12.30M
	EBIT
-6.36M	-21.53M	-40.24M	-20.98M	-24.47M
	EBITDA
-5.65M	-21.06M	-39.38M	-20.90M	-24.47M
	Net Income Common Stockholders
-5.69M	-20.66M	-39.52M	-20.90M	-25.95M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
10.87M	8.68M	26.88M	30.11M	7.23M
	Total Assets
11.59M	10.27M	29.72M	33.63M	18.14M
	Total Debt
0.00	49.00K	69.00K	511.00K	151.00K
	Net Debt
-10.87M	-8.63M	-26.82M	-29.60M	-7.08M
	Total Liabilities
1.66M	3.08M	4.81M	6.50M	10.57M
	Stockholders Equity
9.93M	7.19M	24.91M	27.14M	7.57M
Cash Flow		Free Cash Flow
-4.34M	-19.38M	-36.18M	-20.06M	-35.99M
	Operating Cash Flow
-4.34M	-19.34M	-36.15M	-20.03M	-35.98M
	Investing Cash Flow
0.00	-47.00K	-36.00K	4.48M	32.51M
	Financing Cash Flow
6.53M	1.18M	32.95M	38.44M	2.64M

Fresh Tracks Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.94
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FRTX, the sentiment is Positive. The current price of 0.94 is above the 20-day moving average (MA) of 0.93, above the 50-day MA of 0.82, and above the 200-day MA of 0.82, indicating a bullish trend. The MACD of 0.03 indicates Positive momentum. The RSI at 79.31 is Negative, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FRTX.

Fresh Tracks Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ARQT	54 Neutral	$1.73B	―	-113.76%	―	229.74%	70.23%
Sector *	49 Neutral	$6.86B	0.03	-54.79%	2.48%	24.62%	-2.84%
EYPT	48 Neutral	$448.11M	―	-43.42%	―	-5.97%	-25.87%
NRXP	48 Neutral	$39.75M	―	108.28%	―	―	57.84%
FRTX	42 Neutral	$5.59M	―	-57.34%	―	―	―
RVNC	41 Neutral	$381.02M	―	111.29%	―	15.33%	61.49%